CAMP4 Therapeutics Corporation · NASDAQ:CAMP

CAMP4 Therapeutics — Technical Presentation (September 2021)

7 slides from CAMP4 Therapeutics's technical presentation, September 2021

  1. Slide 1: Oligonucleotide Mediated Upregulation of Serping1 By Targeting Regulatory RNAs

    Oligonucleotide Mediated Upregulation of Serping1 By Targeting Regulatory RNAs Confidential & Proprietary C yn t h i a S m i t h , Yu n J o o n J o n g , A m y J i a n g , S i m r i n K a p o o r, J u s t i n C a r a v e l l a , M a t e o Rodriguez, Rutuja Pai, Bryan Matthews, Jiaqi Huang, David Bum

  2. Slide 2: Upregulating Serping1 for treatment of Hereditary Angioedema

    Upregulating Serping1 for treatment of Hereditary Angioedema HAE is a life-threatening haploinsufficient liver disease Disease Gene ▪ Primarily caused by mutations in SERPING1 encoding C1-INH ▪ SERPING1 is expressed in the liver protein ▪ Functions as a protease inhibitor ▪ Autosomal dominant ▪ the

  3. Slide 3: RNA Actuating Platform (RAP): Targeting regRNA to upregulate gene expression

    RNA Actuating Platform (RAPTM): Targeting regRNA to upregulate gene expression 3 1 2 Map regRNAs in Mouse livers via NGS techniques Identify regRNA Hotspots via screening in Mouse Heps Program for Druggability First- pass 92 42 Leads 3 Optimize Watson Screen ASOs ASOs ASOs Transcriptome analysis Cri

  4. Slide 4: regRNA targeting ASOs upregulate Serping1 in vitro and in vivo

    regRNA targeting ASOs upregulate Serping1 in vitro and in vivo Primary Mouse Hepatocytes Wild-type Mice Serping1 3 CO-2043 CO-2051 mRNA relative to B2m CO-3149 2 Ubel26 1 NTC 0 0.25 0.5 1 2 4 8 Dose uM, free uptake Confidential & Proprietary Scale 50 kb mm10 chr2: 84,750,000 84,800,000 • Male C57/Bl

  5. Slide 5: Achieved Additivity for Serping1 with ASO and ligand combination

    Achieved Additivity for Serping1 with ASO and ligand combination • Utilized a known ligand for Serping1 induction (Interferon gamma) to address regRNA inducibility Serping1 Effect of IFNg on Serping1 Combination of IFNg with regRNA ASOs 10 4 4 mRNA Relative to Geomean IFNg + NTC 9 mRNA mRNA with IFN

  6. Slide 6: ASOs restore expression in haploinsufficient HAE setting

    ASOs restore expression in haploinsufficient HAE setting • Mimicking C1INH-deficiency in vitro: reducing Serping1 to 50% of normal levels Effect of Jak1 inhibitor in Mouse Mouse Hepatocytes Downregulation of Serping1 mRNA Serping1 levels in response to IFNg plus regRNA ASOs 1.5 1.0 mRNA relative to

  7. Slide 7: Conclusion

    Conclusion • CAMP4’s RAP platform identified regRNA that can control Serping1 expression • Identified multiple ASOs targeting the regRNA, that can upregulate the gene expression • In mouse hepatocytes • In mouse livers • Provides a novel approach to treat HAE • The platform provides unique approach

CAMP4 Therapeutics — Technical Presentation (September 2021) on 6ix